AGTC - Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk

• Applied Genetic Technologies Corporation is a mid-clinical-stage biotechnology company developing genetic therapies for rare and debilitating diseases.
• AGTC's initial focus is on ophthalmology (study of medical conditions relating to the eye) where AGTC has active programs for X-linked retinitis pigmentosa, achromatopsia, and optogenetics.
• AGT Corporation is in a reasonable financial position evidenced by 2+ years of cash runway driven by a low-cash burn (TTM: -$53M) and cash of $111M (March 2021).
• XLRP is being targeted by AGTC's lead therapeutic, RPGR, currently in a Phase 2/3 Vista study (data expected: 3Q 22) and a Phase 1/2 expansion trial known as Skyline (data expected: 4Q 21).
• In summary, the author projects Applied Genetic Technologies Corporation as a high-risk "hold".

For further details see: